BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 6819180)

  • 1. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
    Bergquist C; Nillius SJ; Wide L
    Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF; Shoupe D; Mishell DR
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
    Lemay A; Jean C; Faure N
    Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R; Kuhl H; Taubert HD; Sandow J
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic and individualized administration of gonadotropin-releasing hormone agonists plus progestogens: an alternative protocol for contraception.
    Chryssikopoulos A; Phocas I; Rizos D; Kontoravdis A
    Gynecol Endocrinol; 1997 Apr; 11(2):119-26. PubMed ID: 9174853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N; Bastide A
    Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable effects of RU 486 on endometrial maintenance in the luteal phase extended by exogenous hCG.
    Croxatto HB; Salvatierra AM; Croxatto HD; Spitz IM
    Clin Endocrinol (Oxf); 1989 Jul; 31(1):15-23. PubMed ID: 2598478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.
    Laurikka-Routti M; Haukkamaa M; Lähteenmäki P
    Fertil Steril; 1992 Oct; 58(4):680-4. PubMed ID: 1426309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
    Gudmundsson JA; Nillius SJ; Bergquist C
    Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The influence of long-term medication with the LH-RH analogue buserelin on the regulation of the menstrual cycle (author's transl)].
    Hardt W; Schmidt-Gollwitzer M; von der Ohe M; Nevinny-Stickel J
    Geburtshilfe Frauenheilkd; 1981 Nov; 41(11):791-6. PubMed ID: 6797869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.